Camp4 Therapeutics (CAMP) Income towards Parent Company (2023 - 2026)

Camp4 Therapeutics has disclosed Income towards Parent Company across 4 years of filings, most recently posting -$12.2 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$12.2 million, up 2.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$50.0 million (up 3.24% YoY), and the FY2025 annual result was -$50.6 million, up 2.35% from the prior year.
• Income towards Parent Company came in at -$12.2 million for Q1 2026 at Camp4 Therapeutics, down from -$12.1 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$11.7 million in Q3 2023 to a low of -$13.5 million in Q3 2024.
• The 4-year median for Income towards Parent Company is -$12.5 million (2025), against an average of -$12.6 million.
• Across the five-year window, Income towards Parent Company declined 15.29% in 2024 and climbed 9.13% in 2025, its largest moves.
• Camp4 Therapeutics' Income towards Parent Company stood at -$13.0 million in 2023, then retreated by 2.22% to -$13.3 million in 2024, then advanced by 9.13% to -$12.1 million in 2025, then slipped by 0.79% to -$12.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$12.2 million (Q1 2026), -$12.1 million (Q4 2025), and -$13.2 million (Q3 2025), per Business Quant data.